Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.55
(3.77%)
USD 0.55
(3.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.28 Million USD | 52.66% |
| 2022 | -2.7 Million USD | 83.43% |
| 2021 | -16.32 Million USD | -88.05% |
| 2020 | -8.68 Million USD | 51.6% |
| 2019 | -17.94 Million USD | -48.8% |
| 2018 | -12.05 Million USD | -71.21% |
| 2017 | -7.04 Million USD | -77.77% |
| 2016 | -3.96 Million USD | -23.18% |
| 2015 | -3.21 Million USD | -27.05% |
| 2014 | -2.53 Million USD | 76.65% |
| 2013 | -10.84 Million USD | -2454.51% |
| 2012 | -424.36 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.27 Million USD | 277.83% |
| 2024 Q2 | -1.02 Million USD | -142.8% |
| 2023 Q4 | -1.28 Million USD | 52.54% |
| 2023 Q1 | -1.75 Million USD | 35.33% |
| 2023 FY | -1.28 Million USD | 52.66% |
| 2023 Q2 | -5.88 Million USD | -236.51% |
| 2023 Q3 | -2.69 Million USD | 54.17% |
| 2022 FY | -2.7 Million USD | 83.43% |
| 2022 Q3 | -6.94 Million USD | -16.43% |
| 2022 Q2 | -5.96 Million USD | 59.59% |
| 2022 Q4 | -2.7 Million USD | 61.03% |
| 2022 Q1 | -14.75 Million USD | 9.61% |
| 2021 FY | -16.32 Million USD | -88.05% |
| 2021 Q1 | -19.75 Million USD | -127.55% |
| 2021 Q2 | -26.83 Million USD | -35.85% |
| 2021 Q4 | -16.32 Million USD | 18.73% |
| 2021 Q3 | -20.08 Million USD | 25.15% |
| 2020 Q3 | -3.17 Million USD | 70.86% |
| 2020 FY | -8.68 Million USD | 51.6% |
| 2020 Q1 | -5.96 Million USD | 66.73% |
| 2020 Q2 | -10.91 Million USD | -82.85% |
| 2020 Q4 | -8.68 Million USD | -173.08% |
| 2019 Q3 | -28.31 Million USD | 12.52% |
| 2019 Q4 | -17.94 Million USD | 36.65% |
| 2019 FY | -17.94 Million USD | -48.8% |
| 2019 Q1 | -34.76 Million USD | -188.38% |
| 2019 Q2 | -32.37 Million USD | 6.89% |
| 2018 Q1 | -4.05 Million USD | 42.44% |
| 2018 Q4 | -12.05 Million USD | -97.42% |
| 2018 FY | -12.05 Million USD | -71.21% |
| 2018 Q2 | -8.74 Million USD | -115.83% |
| 2018 Q3 | -6.1 Million USD | 30.19% |
| 2017 Q2 | -11.19 Million USD | 28.97% |
| 2017 FY | -7.04 Million USD | -77.77% |
| 2017 Q4 | -7.04 Million USD | 18.46% |
| 2017 Q3 | -8.63 Million USD | 22.87% |
| 2017 Q1 | -15.76 Million USD | -297.97% |
| 2016 Q2 | -548.01 Thousand USD | 67.25% |
| 2016 Q4 | -3.96 Million USD | 34.01% |
| 2016 FY | -3.96 Million USD | -23.18% |
| 2016 Q3 | -6 Million USD | -995.23% |
| 2016 Q1 | -1.67 Million USD | 47.97% |
| 2015 FY | -3.21 Million USD | -27.05% |
| 2015 Q3 | -4.33 Million USD | 34.01% |
| 2015 Q2 | -6.56 Million USD | -43.84% |
| 2015 Q1 | -4.56 Million USD | -80.24% |
| 2015 Q4 | -3.21 Million USD | 25.74% |
| 2014 Q1 | -8.46 Million USD | 21.87% |
| 2014 FY | -2.53 Million USD | 76.65% |
| 2014 Q4 | -2.53 Million USD | 48.77% |
| 2014 Q3 | -4.94 Million USD | 24.81% |
| 2014 Q2 | -6.57 Million USD | 22.43% |
| 2013 Q2 | -461.51 Thousand USD | -208.75% |
| 2013 Q1 | 424.36 Thousand USD | 200.0% |
| 2013 FY | -10.84 Million USD | -2454.51% |
| 2013 Q3 | -12.57 Million USD | -2624.23% |
| 2013 Q4 | -10.84 Million USD | 13.78% |
| 2012 FY | -424.36 Thousand USD | 0.0% |
| 2012 Q4 | -424.36 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 74.09% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 66.422% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 101.199% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 98.282% |
| Azitra, Inc. | -910.04 Thousand USD | -40.763% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | 69.773% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 209.273% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 124.696% |
| CEL-SCI Corporation | 9.42 Million USD | 113.59% |
| iBio, Inc. | -9.75 Million USD | 86.862% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 96.057% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 82.086% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 392.17% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -228.462% |
| NanoViricides, Inc. | -4.79 Million USD | 73.3% |
| Oragenics, Inc. | -3.17 Million USD | 59.6% |
| BiomX Inc. | -772 Thousand USD | -65.933% |
| BiomX Inc. | -772 Thousand USD | -65.933% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 148.394% |
| Palatin Technologies, Inc. | -8.93 Million USD | 85.666% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 109.244% |
| Theriva Biologics, Inc. | -21.02 Million USD | 93.907% |